Five Prime Therapeutics Newswire

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 103 in Five Prime Therapeutics

  1. Galenica to Buy Relypsa for $1.53 Billion to Beef Up in U.S.Read the original story

    Thursday Jul 21 | The Washington Post

    Galenica AG, the owner of Switzerland's biggest pharmacy network, agreed to buy Relypsa Inc. for about $1.53 billion to gain a new medicine and a commercial network in the U.S. The Swiss company will pay $32 per share in cash for Redwood City, California-based Relypsa, it said in a statement Thursday. That's 59 percent above Relypsa's closing price Wednesday of $20.10.

    Comment?

  2. Roche Holding profit rises 4% in first halfRead the original story w/Photo

    Wednesday Jul 20 | MarketWatch

    Roche Holding AG said profit climbed in the first half of the year, buoyed by strong sales across the health care giant's pharmaceutical and diagnostics divisions. Basel, Switzerland-based Roche said net income increased 4% to 5.5 billion Swiss francs in the six months to June 30, beating analyst estimates of 5.3 billion francs.

    Comment?

  3. Five Prime Therapeutics to Announce Second Quarter 2016 Financial...Read the original story

    Monday Jul 18 | P&T Community

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2016 financial results on Thursday, August 4, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m. /1:30 p.m. to discuss the company's financial results and provide a general business update.

    Comment?

  4. Credit Suisse Group AG Reaffirms "Buy" Rating for Five Prime Therapeutics Inc.Read the original story w/Photo

    Saturday Jul 16 | AmericanBankingNews.com

    ... to their positions in the company. Acadian Asset Management LLC bought a new stake in shares of Five Prime Therapeutics during the first quarter worth approximately $20,966,000. RS Investment Management Co. LLC bought a new stake in shares of Five ...

    Comment?

  5. Leerink Swann Reaffirms Buy Rating for Five Prime Therapeutics Inc.Read the original story w/Photo

    Friday Jul 15 | AmericanBankingNews.com

    ... also recently weighed in on FPRX. Oppenheimer Holdings Inc. reissued a "buy" rating on shares of Five Prime Therapeutics in a research note on Monday, April 18th. Jefferies Group reissued a "buy" rating on shares of Five Prime Therapeutics in a ...

    Comment?

  6. GSK Exercises Five Prime License OptionRead the original story w/Photo

    Friday Jul 15 | Contract Pharma Breaking News

    GSK has exercised its option for an exclusive license to a target under the respiratory diseases research collaboration with Five Prime Therapeutics , triggering a $1.5 million payment to Five Prime. The collaboration, established in 2012, aims to identify new therapeutic approaches to treat refractory asthma and chronic obstructive pulmonary disease , with a focus on identifying novel therapeutic targets.

    Comment?

  7. GSK Exclusively Licenses Intellectual Property for Respiratory...Read the original story w/Photo

    Thursday Jul 14 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative protein therapeutics, announced that GSK exercised its option to take an exclusive license to the intellectual property related to a target under the respiratory diseases research collaboration between the companies, triggering a $1.5 million license payment to Five Prime.

    Comment?

  8. Credit Suisse Group AG Reiterates "Buy" Rating for Five Prime Therapeutics Inc.Read the original story w/Photo

    Thursday Jul 14 | Daily Political

    ... bought and sold shares of the company. Adage Capital Partners GP L.L.C. raised its position in Five Prime Therapeutics by 11.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,600,000 shares of the company's stock valued at ...

    Comment?

  9. HPV Testing and Pap Test Market Size Is Projected To Reach $5.6...Read the original story w/Photo

    Wednesday Jul 6 | GlobeNewswire

    HPV Testing and Pap Test Market Size Is Projected To Reach $5.6 Billion By 2024: Grand View Research, Inc. According to the new report published by Grand View Research, the global Human Papillomavirus testing and Pap test market revenue are expected to reach USD 5.6 billion by 2024, the market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer.

    Comment?

  10. Five Prime Therapeutics Receives FDA Orphan Drug Designation for...Read the original story w/Photo

    Tuesday Jul 5 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to FPA144 for the treatment of gastric cancer, including cancer of the gastroesophageal junction in patients whose tumors overexpress FGFR2b. FPA144 is an anti-FGF receptor 2b humanized monoclonal antibody in clinical development as a targeted immune therapy.

    Comment?

  11. #Biotech News: Five Prime Therapeutics (NASDAQ: $FPRX) to Use...Read the original story

    Jun 27, 2016 | InvestorIdeas.com

    June 27, 2016 Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that it will collaborate with distinguished faculty from the University of Minnesota Medical School on a new research project to identify ways to generate hematopoietic stem cells that are capable of being transferred in vivo and regenerating the hematopoietic system. The research is funded by Regenerative Medicine Minnesota.

    Comment?

  12. Global Atopic Dermatitis Market Trends, Size, Growth, Shares And Forecast Research Report 2016Read the original story

    Jun 23, 2016 | Emailwire.com

    Researchmoz added Most up-to-date research on "Global Atopic Dermatitis Market Report: 2016 Edition" to its huge collection of research reports. Atopic dermatitis is a chronic, inflammatory skin disease of unknown origin that usually starts in early infancy, but also affects a substantial number of adults.

    Comment?

  13. Global Next Generation Sequencing Market 2016 Share, Trend, Segmentation and Forecast to 2022Read the original story

    Jun 14, 2016 | World News Report

    PUNE, INDIA, June 14, 2016 / EINPresswire.com / -- The Global Next Generation Sequencing Market accounted for $2.8 billion in 2014 and is expected to grow at a CAGR of 21.7 % to reach $13.5 billion by 2022. Next-generation sequencing enables rapid sequencing and produces millions of DNA and RNA sequences.

    Comment?

  14. Five Prime Therapeutics' (FPRX) "Buy" Rating Reiterated at Credit SuisseRead the original story w/Photo

    Jun 13, 2016 | Daily Political

    A number of other equities analysts also recently issued reports on the company. Oppenheimer reaffirmed a buy rating on shares of Five Prime Therapeutics in a report on Monday, April 18th.

    Comment?

  15. Merck Buys Cough Drug Developer for $1.25BRead the original story

    Jun 10, 2016 | CFO

    Merck has agreed to acquire Afferent Pharmaceuticals for up to $1.25 billion, adding a drug candidate for treating neurogenic conditions including chronic cough to its portfolio. Silicon Valley-based Afferent reported last month that its lead investigational candidate, AF-219, significantly reduced cough frequency in a study of chronic cough patients.

    Comment?

  16. Venture Capitalist Legend Thomas Perkins DiesRead the original story w/Photo

    Jun 9, 2016 | Wall Street Journal

    Thomas Perkins , one of the founding fathers of modern venture capital investing, died in Tiburon, Calif., according to his assistant. He was 84. Mr. Perkins co-founded venture firm Kleiner Perkins Caufield & Byers in 1972, before venture capital was a popular style of investing.

    Comment?

  17. The Wall Street Journal: Venture capital legend Tom Perkins dies at 84Read the original story w/Photo

    Jun 9, 2016 | MarketWatch

    Thomas Perkins, one of the founding fathers of modern venture capital investing, has died, according to his assistant. He was 84. Perkins co-founded venture firm Kleiner Perkins Caufield & Byers in 1972, long before venture capital was a popular style of investing.

    Comment?

  18. Five Prime Therapeutics Inc (FPRX) Earns "Buy" Rating from Credit SuisseRead the original story w/Photo

    Jun 8, 2016 | AmericanBankingNews.com

    ... to their positions in the company. Senzar Asset Management LLC purchased a new position in shares of Five Prime Therapeutics during the fourth quarter valued at approximately $5,625,000. Granite Point Capital Management L.P. acquired a new position ...

    Comment?

  19. Five Prime Therapeutics Announces Updated Data in Mesothelioma...Read the original story w/Photo

    Jun 4, 2016 | GlobeNewswire

    Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturing There are more than 50% of mesothelioma patients who are on trial and continue to be followed SOUTH SAN FRANCISCO, Calif., June 04, 2016 -- Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing Phase 1b trial of FP-1039/GSK3052230 in mesothelioma patients were reported today in a poster presentation at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

    Comment?

  20. Study Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer MedicineRead the original story w/Photo

    Jun 3, 2016 | Wall Street Journal

    This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

    Comment?